Novo Nordisk Sues Pharmacies Over Knock-Off Wegovy, Pressuring Telehealth Providers
Weight loss drug maker Novo Nordisk has sued at least three compounding pharmacies selling unauthorized generic versions of its GLP-1 therapy Wegovy, seeking injunctions and undisclosed damages. The legal action underscores mounting industry scrutiny over safety and liability that could tighten access through telehealth providers like Hims & Hers.
1. Lawsuit Filed Against Compounding Pharmacies
Novo Nordisk initiated legal proceedings against three compounding pharmacies accused of producing and distributing unlicensed generic versions of its GLP-1 weight loss therapy Wegovy. The company is pursuing injunctions to halt sales and unspecified monetary relief for alleged patent infringement and potential safety risks.
2. Implications for Telehealth Access
The lawsuit highlights growing concerns over unauthorized GLP-1 formulations and may prompt tighter regulatory oversight of compounded medications. Telehealth providers such as Hims & Hers, which facilitate remote prescribing and delivery of weight loss treatments, could face new compliance requirements or supply disruptions.